A risky bet on a long-delayed CAR-T drug now faces a do-or-die deadline — where any slip can kill a $9 CVR
The deadline for an FDA approval of Bristol Myers’ CAR-T drug liso-cel is going right down to the wire.
The pharma giant put out the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
